Trilogy Metals posts wider quarterly loss amid federal investment progress

Trilogy Metals Inc. (TSX: TMQ) (NYSE American: TMQ) reported a net loss of $7.1 million for the first quarter ended February 28, 2026, compared to a $3.6 million loss in the same period last year, according to the company's earnings statement.

The Vancouver-based metals exploration company attributed the increased loss primarily to two non-cash items: a $1.5 million mark-to-market adjustment related to its obligation to issue shares and warrants to the U.S. Department of War, and higher stock-based compensation charges from annual equity grants.

Trilogy maintained a cash balance of $47.8 million as of February 28, 2026. The company operates through a 50/50 joint venture called Ambler Metals LLC with South32 Limited, focusing on the Upper Kobuk Mineral Projects in northwestern Alaska.

The company continues to advance a $35.6 million strategic investment from the U.S. Department of War. Under the binding letter of intent, $17.8 million would go to Trilogy for shares and warrants, while $17.8 million would go to South32 for existing shares and a call option. The parties extended the deadline to May 31, 2026, to complete closing conditions including a Foreign Ownership, Control, or Influence review.

During the quarter, the U.S. Department of the Interior opened approximately 2.1 million acres to mineral entry through Public Land Order 7966, including federal lands along the proposed Ambler Access Project corridor. U.S. Interior Secretary Doug Burgum indicated the White House is considering participating in Ambler Road financing, potentially as an equity partner.

Ambler Metals announced four senior appointments in February 2026, including Michael Galicki as VP Exploration and Cole Schaeffer as VP Human Resources, Community and Partnerships, to support the approved $35 million work program.

For fiscal 2026, Trilogy has budgeted $22.5 million total, comprising $5.0 million for corporate activities and $17.5 million for Ambler Metals project funding. The company's annual general meeting is scheduled for May 13, 2026, in Vancouver, British Columbia.

You May Also Be Interested In

• Matinas BioPharma to merge with GH Power, sell drug unit to Azurity
• Repay Holdings adds Parthenon Capital partner to its board
• BioMarin completes acquisition of Amicus Therapeutics